TETRALONE DERIVATIVES AS ANTITUMOR AGENTS
    6.
    发明公开
    TETRALONE DERIVATIVES AS ANTITUMOR AGENTS 审中-公开
    TETRALONDERIVATE ALS ANTITUMORMITTEL

    公开(公告)号:EP1349830A1

    公开(公告)日:2003-10-08

    申请号:EP01999552.1

    申请日:2001-12-06

    IPC分类号: C07C259/06 A61K31/165

    摘要: Compounds of formula (I) wherein R1, R2, R3, R4, R5, X and Y have the meanings defined below, process of manufacturing these compounds and pharmaceuticals containing such a compound have HDAC inhibitor activity. R1 is selected from hydrogen, (1-4C)alkyl, COOH, COO(1-4C)alkyl, R2, R3, R4, R5 are independently selected from hydrogen, a halogen atom, an (1-4C)alkyl-, trifluoromethyl-, hydroxy-, (1-4C)alkoxy-, aryloxy-, arylalkyloxy-, nitro-, amino-, (1-4C)alkylamino-, di[1-4C)alkyl]-amino, piperidino, morpholino, pyrrolidino, (1-4C)alkanoylamino-, or an aryl group, or a heteroaryl group, or R2 and R3 together or R3 and R4 together or R4 and R5 together, respectively, can form an (1-3C)alkylenedioxy ring, or R2 and R3 together or R3 and R4 together or R4 and R5 together, respectively, can form an (3-5C)alkylene chain. Y is CH2-CH2-. X is an alkylene-chain of 4 to 10 carbon atoms which can be saturated or unsaturated with one or two double bonds or one or two triple bonds or a one double and one triple bond, and which can be branched or unbranched or interrupted by a (3-7C) cycloalkylring.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R1,R2,R3,R4,R5,X和Y具有本说明书中定义的含义。 该化合物具有可用于癌症治疗的组蛋白脱乙酰酶(HDAC)抑制活性。 还提供了通过使式III化合物与式IV化合物反应制备式I化合物的方法,其中A是可置换基团,PG是保护基团。